Crizotinib (Xalkori(Registered)) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients With Solid Or Hematologic Malignancies That Harbor A Crizotinib-sensitive Molecular Alteration But Who Are Unable To Swallow Crizotinib Capsules

Trial Profile

Crizotinib (Xalkori(Registered)) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients With Solid Or Hematologic Malignancies That Harbor A Crizotinib-sensitive Molecular Alteration But Who Are Unable To Swallow Crizotinib Capsules

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Crizotinib (Primary)
  • Indications Haematological malignancies; Solid tumours
  • Focus Expanded access; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 14 Jan 2017 Status changed from suspended to recruiting.
    • 18 Jun 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top